Repotrectinib

2024 saw progress in pancreatic cancer treatment with four new drug approvals, a phase 3 trial showing survival benefits, and the first phase 3 RAS inhibitor trial. The five-year survival rate rose to 13%, though pancreatic cancer remains challenging. Targeted therapies and biomarker testing are crucial, with new options like NALIRIFOX, KRAS inhibitors, and TTFields offering hope.

MSKCC advanced cancer treatments in 2024 include new surgical techniques, vaccines, drugs enhancing radiation, and diagnostic tools. The FDA approved 11 drugs based on MSK's pivotal clinical trials, covering new uses for existing drugs, effective drug combinations, engineered cell therapies, and novel targeted therapies. Key developments include a KRAS vaccine for pancreatic and colorectal cancer, combination drug-radiation treatment for basal cell carcinoma, noninvasive E-nose for lung cancer detection, improved transplant success with partially matched donors, exercise impact on prostate cancer biomarkers, new imaging for lung and prostate cancers, TIL therapy for non-small cell lung cancer, robotic neurosurgery for spinal tumors, avoiding surgery for HPV throat cancer with innovative radiation, imlunestrant for ER+, HER2- advanced breast cancer, mRNA vaccine for pancreatic cancer, and immunotherapy for rectal cancer. FDA approvals included tepotinib for METex14 lung cancer, CAR T treatment for mantle cell lymphoma, selpercatinib for RET-linked thyroid cancer, repotrectinib for NTRK fusion cancers, adagrasib with cetuximab for KRAS-G12C colorectal cancer, afamitresgene autoleucel for synovial sarcoma, vorasidenib for IDH glioma, inavolisib with fulvestrant and palbociclib for breast cancer, revumenib for KMT2A leukemia, zanidatamab for HER2 biliary tract cancer, and zenocutuzumab for NRG1 fusion pancreatic and lung cancers.

Taletrectinib, a next-gen ROS1 TKI, shows superior efficacy, CNS penetration, and safety in ROS1+ NSCLC, with TRUST-I trial data revealing 90.6% ORR in TKI-naive patients and 51.5% in crizotinib-pretreated. TRUST-II global trial supports consistent activity and safety, with pooled analysis confirming taletrectinib's benefit as a first-line option.

Osler Research Institute for Health Innovation conducts over 70 clinical trials, including new cancer treatments, aiming to revolutionize healthcare in Brampton and beyond. Breakthroughs like liquid biopsy reduce diagnosis time from weeks to days, enabling tailored patient care. Trials span oncology, cardiology, hepatology, infections diseases, and pediatrics, addressing community health needs and supporting medical education.

Healthcare industry growth driven by drug development, technology adoption, and R&D investments. Key stocks include Johnson & Johnson, Merck, and Bristol-Myers Squibb. Pharmaceuticals market to reach $1.45 trillion by 2029. Technologies like AI, telemedicine, and robotics revolutionize patient care. JNJ, MRK, and BMY highlighted for strong growth and innovation.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but with stricter controls. Biosimilars, including Humira’s, have struggled with adoption despite cost savings potential. Optum Rx also adds and removes various oncology and CNS medications for 2025.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but is subject to prior authorization. Biosimilars have struggled with low adoption despite cost advantages, but large PBMs like CVS Health are shifting towards biosimilars. Optum Rx also adds and removes various oncology and CNS medications from its 2025 formulary.

Taletrectinib (AB-106) demonstrated durable responses in ROS1-positive NSCLC patients in the TRUST-II trial, overcoming resistance mutations and reducing off-target AEs compared to other ROS1 TKIs.

Beijing Avistone Biotechnology announces FDA clearance of ANS03, a next-gen TKI targeting ROS1 and NTRK, designed to overcome resistance in ROS1/NTRK fusion-positive cancers. Enrollment for advanced or metastatic tumor patients with ROS1 or NTRK alterations is expected in Q1 2025.